Singapore

Since 2001, Sun Pharma has been serving Singapore for over two decades, providing high‑quality, trusted, and accessible medicines across a broad range of therapeutic areas. Our established portfolio supports patient care in anti‑infectives, cardiovascular and metabolic disorders (including anti‑hypertensives, anti‑hyper lipidemics and anti‑platelet therapies), gastroenterology, selective COX‑2 inhibitors, neurology, urology, and oncology, reinforcing our long‑standing commitment to meeting the needs of healthcare professionals and patients across the healthcare continuum.

In 2026, Sun Pharma began introducing innovative branded therapies in Singapore, marking an important milestone in our journey. This expansion commenced with the launch of a biologic therapy indicated for moderate to severe psoriasis, alongside a strong pipeline of future innovations. Through these advancements, we aim to ensure that Singaporean patients have greater access to cutting‑edge treatments backed by robust science and global expertise.

Beyond medicines, Sun Pharma remains committed to making a positive impact within the community. We actively support disease awareness and patient education initiatives through participation in community outreach programmes organised in collaboration with patient advocacy groups and non‑profit organisations, reflecting our belief in responsible healthcare engagement and holistic patient support.